Dundore R L, Habeeb P G, Pratt P F, Becker L T, Clas D M, Buchholz R A
Department of Cardiovascular Pharmacology, Sterling Winthrop Pharmaceuticals Research Division, Rensselaer, New York 12144.
J Cardiovasc Pharmacol. 1992 Jun;19(6):937-44. doi: 10.1097/00005344-199206000-00015.
Selective inhibition of either the low Km cyclic AMP (cAMP) or low Km cyclic GMP (cGMP) phosphodiesterase (PDE) promotes vasorelaxation and, consequently, produces depressor effects. To evaluate the systemic and regional hemodynamic effects of selective inhibitors of these PDE isozymes, CI-930 (0.1-10 mg/kg), an inhibitor of low Km cAMP PDE, or zaprinast (3-30 mg/kg), an inhibitor of low Km cGMP PDE, was given i.v. to conscious, normotensive rats. The rats were chronically instrumented with vascular catheters and either an ultrasonic transit-time flow probe around the ascending aorta or miniaturized pulsed Doppler flow probes around the superior mesenteric and left renal arteries and the abdominal aorta. CI-930 and zaprinast, at cumulative doses of 3 and 30 mg/kg, respectively, produced comparable reductions in mean arterial pressure (-22 +/- 3 and -19 +/- 4 mm Hg, respectively) and total peripheral resistance (-0.41 +/- 0.07 and -0.42 +/- 0.06 mm Hg/ml/min, respectively) but affected other hemodynamic variables differently. CI-930 at 3 mg/kg increased the heart rate (HR), maximal aortic flow acceleration (dF/dt), and peak aortic flow and decreased the stroke volume (SV). Cardiac output (CO) was not affected by CI-930. Zaprinast at 30 mg/kg increased the CO, dF/dt, and peak aortic blood flow. The HR and SV were unaffected by zaprinast. Although both CI-930 and zaprinast increased the dF/dt and peak aortic flow, these parameters were affected more by CI-930 than by zaprinast. CI-930 decreased hindquarter, mesenteric, and renal vascular resistances in a dose-dependent manner.(ABSTRACT TRUNCATED AT 250 WORDS)
选择性抑制低 Km 环磷酸腺苷(cAMP)或低 Km 环磷酸鸟苷(cGMP)磷酸二酯酶(PDE)可促进血管舒张,进而产生降压作用。为评估这些 PDE 同工酶选择性抑制剂的全身和局部血流动力学效应,将低 Km cAMP PDE 抑制剂 CI-930(0.1 - 10 mg/kg)或低 Km cGMP PDE 抑制剂扎普司特(3 - 30 mg/kg)静脉注射给清醒的正常血压大鼠。这些大鼠长期植入血管导管,并在升主动脉周围植入超声渡越时间血流探头,或在上肠系膜动脉、左肾动脉及腹主动脉周围植入小型脉冲多普勒血流探头。CI-930 和扎普司特分别以累积剂量 3 和 30 mg/kg 给药时,平均动脉压分别有相当程度的降低(分别为 -22 ± 3 和 -19 ± 4 mmHg),总外周阻力也分别降低(分别为 -0.41 ± 0.07 和 -0.42 ± 0.06 mmHg/ml/min),但对其他血流动力学变量的影响不同。3 mg/kg 的 CI-930 可增加心率(HR)、最大主动脉血流加速度(dF/dt)和主动脉血流峰值,并降低 stroke volume(SV)。CI-930 对心输出量(CO)无影响。30 mg/kg 的扎普司特可增加 CO、dF/dt 和主动脉血流峰值。扎普司特对 HR 和 SV 无影响。尽管 CI-930 和扎普司特均增加了 dF/dt 和主动脉血流峰值,但这些参数受 CI-930 的影响比受扎普司特的影响更大。CI-930 以剂量依赖方式降低后肢、肠系膜和肾血管阻力。(摘要截短于 250 字)